You are here:Home/Greg Koski – Faculty – IFAPP Academy
Greg Koski, PhD, MD
Greg Koski, PhD MD, CEO of the Alliance for Clinical Research Excellence & Safety (ACRES), is also Associate Professor of Anesthesia, Harvard Medical School and Honorary Anesthetist, Massachusetts General Hospital, expert faculty for Partners HealthCare International (PHI), and Senior Scientist at the James Mongan Institute for Health Policy.
As the first director of the Office of Human Research Protections (OHRP) at the U.S. Department of Health and Human Services, Koski championed a “culture of conscience” in human research, emphasizing the values and processes of professionalism and quality improvement, moving beyond mere regulatory compliance and created the Program of International Activities within the OHRP to enhance its global effectiveness.
He has worked with many global organizations including the World Health Organization (WHO) and the World Medical Association to coordinate and strengthen global mechanisms for ethical conduct of human research and clarifying the intent and applicability of the Declaration of Helsinki and was influential in development of accreditation for human research protections programs and certification of physician investigators.
An internationally-recognized, scientist, speaker and author, Koski has received multiple awards for his inspiring leadership, most recently the Lifetime Service Award from Partnerships in Clinical Trials and was named in 2017 among PharmaVoice 100 “Most Inspiring Persons” for his many contributions to academic medicine and clinical research.
The Alliance for Clinical Research Excellence and Safety, a non-profit multi-stakeholder global collaborative, is working in the public interest to build a comprehensive integrated system for accelerating the discovery, development, and effective use of medicines worldwide.
IFAPP Academy provides an online, continuing professional development course, Medical Affairs in Medicines Development, resulting in the Professional Certification, Certified Medicines Development (CMD).